Show simple item record

dc.contributor.authorSarink, Danja
dc.contributor.authorSchock, Helena
dc.contributor.authorJohnson, Theron
dc.contributor.authorOvervad, Kim
dc.contributor.authorHolm, Marianne
dc.contributor.authorTjønneland, Anne
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorHis, Mathilde
dc.contributor.authorKvaskoff, Marina
dc.contributor.authorBoeing, Heiner
dc.contributor.authorLagiou, Pagona
dc.contributor.authorPapatesta, Eleni-Maria
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorPalli, Domenico
dc.contributor.authorPala, Valeria
dc.contributor.authorMattiello, Amalia
dc.contributor.authorTumino, Rosario
dc.contributor.authorSacerdote, Carlotta
dc.contributor.authorBueno-de-Mesquita, H B As
dc.contributor.authorvan Gils, Carla H
dc.contributor.authorPeeters, Petra H
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorAgudo, Antonio
dc.contributor.authorSánchez, Maria-José
dc.contributor.authorChirlaque, Maria-Dolores
dc.contributor.authorArdanaz, Eva
dc.contributor.authorAmiano, Pilar
dc.contributor.authorKhaw, Kay Tee
dc.contributor.authorTravis, Ruth
dc.contributor.authorDossus, Laure
dc.contributor.authorGunter, Mark
dc.contributor.authorRinaldi, Sabina
dc.contributor.authorMerritt, Melissa
dc.contributor.authorRiboli, Elio
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorFortner, Renée T
dc.date.accessioned2018-03-08T11:10:20Z
dc.date.available2018-03-08T11:10:20Z
dc.date.issued2017-09
dc.identifier.citationCirculating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. 2017, 10 (9):525-534 Cancer Prev Res (Phila)en
dc.identifier.issn1940-6215
dc.identifier.pmid28701332
dc.identifier.doi10.1158/1940-6207.CAPR-17-0125
dc.identifier.urihttp://hdl.handle.net/10029/621554
dc.description.abstractReceptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+),n= 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet= 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63);Ptrend= 0.20], but not ER- disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR- disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14);Ptrend= 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.Cancer Prev Res; 10(9); 525-34. ©2017 AACR.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer prevention research (Philadelphia, Pa.)en
dc.titleCirculating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.en
dc.typeArticleen
dc.identifier.journalCancer Prev Res 2017; 10(9):525-34en
html.description.abstractReceptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+),n= 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet= 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63);Ptrend= 0.20], but not ER- disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR- disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14);Ptrend= 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.Cancer Prev Res; 10(9); 525-34. ©2017 AACR.


This item appears in the following Collection(s)

Show simple item record